Measuring Blood Vessel Density in the Optic Nerve of Multiple Sclerosis Patients With OCTA
Quantitative OCT Angiography Differences in Optic Nerve Vascular Density in Multiple Sclerosis: A Case-Control Study
The goal of this observational study is to learn about the effect of multiple sclerosis on the blood flow of the optic nerve of affected patients compared to normal subjects by OCTA. The main question it aims to answer is:
- Does MS change the blood flow in the optic nerve?
- If it does, can measuring this blood flow be used as a simple sign (a biomarker) to help doctors understand and manage MS?
We used a quick and painless eye scan called Optical Coherence Tomography Angiography (OCTA). This special scan takes detailed pictures of the blood vessels in the optic nerve without needing any injections. We performed this scan on two groups of people: one group with MS and one group without MS, and then compare the results.
In simple terms, why is this important? If we can show that MS affects the optic nerve blood vessels, it could give us a new, quick way to monitor the disease and see how it is progressing, just by doing a simple eye scan.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The optic nerve is like the main cable that carries visual information from the eye to the brain. In Multiple Sclerosis (MS), the body's immune system mistakenly attacks the protective covering (called myelin) around nerve fibers, including those in the optic nerve. This often causes a condition called optic neuritis, which can lead to vision loss.
While we know MS damages the nerve fibers, we are now trying to understand how it affects the blood vessels that supply oxygen and nutrients to the optic nerve. Are these blood vessels damaged as well? Does reduced blood flow contribute to the nerve damage?
2. The Technology We Are Using
This study uses a advanced, non-invasive imaging technology called Optical Coherence Tomography Angiography (OCTA).
What it does: The OCTA machine uses a safe, dim light beam to scan the optic nerve and macula. It works like a microscopic radar for blood vessels, allowing us to create very detailed, high-resolution 3D maps of the blood flow in the retina and optic nerve without any needles or injections.
What we measure: From these maps, we can quantitatively analyze the vessel density which is a percentage that tells us how much of a specific area is filled with functioning blood vessels. We will focus this measurement on the Radial Peripapillary Capillaries, which are the blood vessels that directly supply the optic nerve head.
3. The Purpose and Potential Impact of This Research
The main goal of this study is to determine if the blood vessel density in the optic nerve is a reliable biological marker (or biomarker) for MS.
A biomarker is an objective, measurable sign of a medical condition. If we can prove that changes in optic nerve blood flow are a consistent marker of MS, it could provide us with:
A new tool to help understand the disease activity in an individual.
A quick and painless way to potentially monitor how the disease is changing over time and whether treatments are effectively protecting the nervous system.
By comparing these detailed OCTA measurements between participants with and without MS, we hope to better understand the role of blood flow in the disease and contribute to improved future care for people living with MS.
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
Faiyum Governorate
-
Al Fayyum、Faiyum Governorate、エジプト、63514
- Fayoum University hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- group 1; patients with multiple sclerosis with optic neuritis.
- group 2; normal healthy age matched controls
Exclusion Criteria:
- Other optic nerve diseases as glaucoma, papilledema or conginetal anomalies.
- Other macular diseases as AMD, CSR, scars …
- Errors of refraction outside +4 and -6 D range.
- Media opacity as cataracts or corneal opacities that may interfere with the quality of scans.
- Signal strength index less than 4\10.
研究計画
研究はどのように設計されていますか？
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Multiple Sclerosis (MS) Cohort
26 eyes of patients with clinically definite MS
|
optic nerve head analysis as regards the vessel density and retinal nerve fiber layer thickness and ganglion cell complex analysis as regards thickness and focal loss volume and global loss volume.
|
|
Healthy Control Cohort
28 eyes of age- and sex-matched normal subjects
|
optic nerve head analysis as regards the vessel density and retinal nerve fiber layer thickness and ganglion cell complex analysis as regards thickness and focal loss volume and global loss volume.
|
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
vessel density of the optic nerve head and peripapillary region measured by OCTA
時間枠：Baseline
|
Difference in microvascular vessel density, as measured by Optical Coherence Tomography Angiography (OCTA), in the optic nerve head and peripapillary region between patients with Multiple Sclerosis and healthy controls.
Analysis will include the whole disc area, inside the disc, and individual quadrants.
|
Baseline
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
RNFL thickness
時間枠：Baseline
|
Retinal Nerve Fiber Layer (RNFL) thickness, measured in micrometers, for the superior and inferior hemispheres of the optic nerve head.
|
Baseline
|
|
GCC thickness
時間枠：Baseline
|
The thickness of the macular Ganglion Cell Complex (GCC) was measured in micrometers for the superior and inferior hemispheres.
These measurements were then analyzed by the device's proprietary software to calculate the Focal Loss Volume (FLV) and Global Loss Volume (GLV) indices.
|
Baseline
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- R687
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。